Oncology News Articles

▼ Show details

The latest Cancer and Oncology news articles published daily by MDLinx physician editors who comb through the top peer-reviewed clinical journals for the medical articles that will make a difference to you and your practice. Organized by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants can stay current on latest oncology topics, symptoms, treatments, risk factors in Cancer and Hematology.

New! >> Start your free Oncology Board Exam Prep course now.
Ranked, sorted, and summarized by MDLinx editors from the latest literature
Topics:

1 A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist The Journal of Rheumatology, September 19, 2014    Evidence Based Medicine    Clinical Article

2 Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma Journal of Clinical Oncology, September 19, 2014    Clinical Article

3 Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial The Lancet, September 19, 2014    Evidence Based Medicine    Clinical Article

4 A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study) The Breast, September 19, 2014    Clinical Article

5 Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines Full Text Translational Lung Cancer Research, September 19, 2014    Clinical Guideline

6 Adverse event management of oral mucositis in patients with breast cancer Breast Care, September 19, 2014    Review Article

7 Interpret and manage (not only autoimmune) cytopenias in primary immunodeficiencies: Pathomechanisms, novel differential diagnoses, and treatment Blood, September 19, 2014    Clinical Article

8 The impact of open versus laparoscopic resection for colon cancer on C-reactive protein concentrations as a predictor of postoperative infective complications Annals of Surgical Oncology, September 19, 2014    Clinical Article

9 Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies Urologia Internationalis, September 19, 2014    Clinical Article

10 Role of PSA density in diagnosis of prostate cancer in obese men International Urology and Nephrology, September 19, 2014    Clinical Article

11 Conventional vs. waterjet-assisted endoscopic submucosal dissection in early gastric cancer: A randomized controlled trial Endoscopy, September 19, 2014    Clinical Article

12 Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (alliance) prospective multicenter clinical trial Annals of Surgery, September 19, 2014    Review Article

13 How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies Current Opinion in Endocrinology, Diabetes and Obesity, September 19, 2014    Clinical Article

14 The value of the pretreatment neutrophil lymphocyte ratio vs. platelet lymphocyte ratio in predicting the long-term survival in colorectal cancer Cancer Biomarkers, September 19, 2014    Clinical Article

15 Prognostic significance of DNMT3A mutations in patients with acute myeloid leukemia Blood Cells, Molecules, and Diseases, September 19, 2014    Clinical Article

16 Over-expression of a poor prognostic marker in prostate cancer: AQP5 promotes cells growth and local invasion Full Text World Journal of Surgical Oncology, September 19, 2014    Clinical Article

17 Diagnostic significance of diffusion-weighted MRI in patients with cervical cancer: A meta-analysis Tumor Biology, September 19, 2014    Evidence Based Medicine

18 CyberKnife stereotactic body radiotherapy and CyberKnife accelerated partial breast irradiation for the treatment of early breast cancer Full Text Translational Cancer Research , September 19, 2014    Review Article

19 Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: An alternative treatment option British Journal of Cancer, September 19, 2014    Clinical Article

20 Nestin involvement in tissue injury and cancer - a potential tumor marker? Cellular Oncology, September 19, 2014    Clinical Article

50 available pages FirstPrevious 1 2 3 4 5 6 7 8 9 10 Next Last

Clinical Pearls in Oncology

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Highlights in Oncology

YKL-40 predicts poor prognosis for bladder cancer

As reported in Urologic Oncology, the gene expression and serum level of YKL-40 are higher in patients with bladder cancer than healthy controls. Serum YKL-40 levels predict poor prognosis in patients with muscle-invasive bladder cancer (HR=1.75).

Increased incidence of second primary cancers in patients with salivary gland tumors

As reported in JAMA—Otolaryngology-Head & Neck Surgery, patients with salivary gland tumors have an increased risk of second primary tumors and newly developed cancers. Specifically, the cumulative 2-, 5-, and 10-year rates for second primary cancers are 4.4%, 8.3%, and 12.4%, respectively. Similarly, the cumulative 2-, 5-, and 10-year rates for newly diagnosed cancers are 1.1%, 3.4%, and 10.5%, respectively.

CTC count predicts survival in mBC

As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).


Other Topics in Oncology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close